
    
      -  MRI's will be performed at specific time points during the participants treatment for
           renal cell carcinoma with the drug sunitinib or pazopanib. These ASL MRI's will be
           performed at baseline, 2 weeks upon initiation of therapy with sunitinib/pazopanib,
           after cycle 2 and/or cycle 4 of therapy, and at the end of therapy.

        -  The MRI tests for all participants will be done at Beth Israel Deaconess Medical Center.
    
  